Introduction：Basic information about CAS 83015-26-3|Atomoxetine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Atomoxetine |
|---|
| CAS Number | 83015-26-3 | Molecular Weight | 255.355 |
|---|
| Density | 1.0±0.1 g/cm3 | Boiling Point | 389.0±37.0 °C at 760 mmHg |
|---|
| Molecular Formula | C17H21NO | Melting Point | / |
|---|
| MSDS | / | Flash Point | 164.1±16.0 °C |
|---|
Names
| Name | atomoxetine |
|---|
| Synonym | More Synonyms |
|---|
Atomoxetine BiologicalActivity
| Description | Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na+ channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research[1][2][3]. |
|---|
| Related Catalog | Signaling Pathways >>Membrane Transporter/Ion Channel >>Sodium ChannelResearch Areas >>Neurological DiseaseSignaling Pathways >>Neuronal Signaling >>Serotonin Transporter |
|---|
| In Vitro | Atomoxetine (Tomoxetine) (1-100 µM; 0.5-20 seconds; tsA201 cells) interacts with the human heart muscle sodium channel (hNav1.5) in a state and dose-dependent manner[2]. |
|---|
| In Vivo | Atomoxetine (Tomoxetine) (0.3-3 mg/kg; i.p.; 0-4 hours; male Sprague-Dawley rats) increases extracellular norepinephrine and dopamine by 3-fold and increases Fos expression in the rat prefrontal cortex[1]. Atomoxetine (Tomoxetine) (0.1-5 mg/kg; i.p. and p.o; for 14 days; spontaneously hypertensive rat) can improve behaviors associated with ADHD in rats[3]. Animal Model: Male Sprague-Dawley rats[1] Dosage: 0.3, 1 and 3 mg/kg Administration: Intraperitoneal injection; for 4 hours Result: Increased the number of cells expressing Fos-like immunoreactivity in PFC 3.7-fold and increased extracellular norepinephrine and dopamine by 3-fold. Animal Model: Spontaneously hypertensive rat (SHR)[3] Dosage: 0.1, 0.3, 1.25 and 5.0 mg/kg Administration: Intraperitoneal injection and oral administration; for 14 days Result: Had non-impact on the measurement of motor activity. |
|---|
| References | [1]. Turner M, et, al. Effects of atomoxetine on locomotor activity and impulsivity in the spontaneously hypertensive rat. Behav Brain Res. 2013 Apr 15;243:28-37. [2]. Föhr KJ, et, al. Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner. Front Pharmacol. 2021 Feb 25;12:622489. [3]. Bymaster FP, et, al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. |
|---|
Chemical & Physical Properties
| Density | 1.0±0.1 g/cm3 |
|---|
| Boiling Point | 389.0±37.0 °C at 760 mmHg |
|---|
| Molecular Formula | C17H21NO |
|---|
| Molecular Weight | 255.355 |
|---|
| Flash Point | 164.1±16.0 °C |
|---|
| Exact Mass | 255.162308 |
|---|
| PSA | 21.26000 |
|---|
| LogP | 3.28 |
|---|
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |
|---|
| Index of Refraction | 1.552 |
|---|
| InChIKey | VHGCDTVCOLNTBX-QGZVFWFLSA-N |
|---|
| SMILES | CNCCC(Oc1ccccc1C)c1ccccc1 |
|---|
Safety Information
| Safety Phrases | S22-S24/25 |
|---|
| HS Code | 2922299090 |
|---|
Customs
| HS Code | 2922299090 |
|---|
| Summary | 2922299090. other amino-naphthols and other amino-phenols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|---|
Synonyms
| Hismanal(R) |
| [3H]-Astemizole |
| MFCD00865352 |
| benzenepropanamine, N-methyl-g-(2-methylphenoxy)-, (gR)- |
| Laridal |
| (3R)-N-Methyl-3-(2-methylphenoxy)-3-phenyl-1-propanamine |
| Histaminos |
| astemizole |
| 1-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-1H-benzimidazole-2-amine |
| Paralergin |
| (gR)-N-Methyl-g-(2-methylphenoxy)benzenepropanamine |
| tomoxetine [INN_en] |
| 1-(4-fluorophenylmethyl)-N-{1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl}-1H-benzimidazol-2-amine |
| [14C]-Atomoxetine |
| (R)-N-methyl-3-(2-tolyloxy)-3-(phenyl)propylamine |
| (-)-Tomoxetine |
| Tomoxetine [INN] |
| Retolen |
| Alermizol |
| [14C]-Astemizole |
| (R)-Tomoxetine |
| (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine |
| Atomoxetine |
| Astemison |
| Astemizolum |
| Benzenepropanamine, N-methyl-γ-(2-methylphenoxy)-, (γR)- |
| Astemizol |
| Hismanal |
